To investigate the potential of NLRX1 as a therapeutic target for MS, a recombinant form of NLRX1 was created by fusing the LRR region of NLRX1 with a blood brain barrier (BBB)-penetrable peptide dNP2 [55]. Here, NLRX1 is linked to myeloid sarcoma.